BIO-Europe Spring® 2016 Event in Sweden this April will bring 2,000+ life science executives to Stockholm-Uppsala region

The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016. Organized by EBD Group, the event is co-hosted by Stockholm Business Region and Stockholm Science City Foundation.

The Stockholm-Uppsala region, defined as the three counties of Uppsala, Stockholm and Sörmland, is one of the largest life science clusters in Europe, and Scandinavia’s leading life science cluster. It is also one of the world’s most productive with an astounding 15–20 new life science companies formed on average in the region each year over the last decade.

“The Stockholm-Uppsala region offers life science companies access to cutting-edge research, unique competence and an infrastructure that brings innovations to patients,” said Ylva Williams, CEO of Stockholm Science City Foundation. “Our strength is in collaboration, where the industry have access to healthcare and patients through test beds. Sweden is an excellent choice for production of biologics, pilots within healthcare as well as for clinical trials. ”

“Stockholm is an active life science cluster with over 600 companies based in the region, including industry leaders such as AstraZeneca and GE Healthcare,” said Anna Chrisman, Group Managing Director, EBD Group. “As an innovation center for stem cell therapies, digital health and drug development R&D, it is the perfect place to hold BIO-Europe Spring.”

BIO-Europe Spring is premier springtime partnering conference serving the global biotechnology industry and is facilitated by EBD Group’s partneringONE®, the gold standard one-to-one networking solution for the life sciences.

One-to-one partnering meetings are a key business strategy that has transformed the drug development industry in bringing together innovators and visionaries with seasoned experts from every corner of the globe. Company presentations by early stage projects, innovative startups, established biotechs and midsize pharma companies are also a focus of the event and enable innovators to present directly to potential investors, pharma and development partners.

International large and midsize pharma companies already confirmed to attend include AbbVie, Alexion Pharmaceuticals, Almirall, Amgen, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Fine Foods & Pharmaceuticals, Ironwood Pharmaceuticals, Johnson & Johnson, LES LABORATOIRES SERVIER,  Merck Serono, a division of Merck KGaA, Darmstadt, MSD, Novartis Pharma, Novo Nordisk, Pfizer, Pierre Fabre Medicament, Roche, Sanofi, Takeda Pharmaceutical Company Ltd, and Upsher Smith.

The 2015 edition featured 12,439 one-to-one partnering meetings. Over 2,300 delegates from 1,367 companies representing 53 countries attended. There were 129 company presentations with 2,672 licensing opportunities on offer, and 68 exhibitors at the event.

Registration information for BIO-Europe Spring is available online.